TEXT

Figure3.pzfx (89.29 kB)

DATASET

Figure 3 A 1-wk Glucose.xlsx (21.95 kB)

DATASET

Figure 3 B 1-wk Insulin.xlsx (443.75 kB)

DATASET

Figure 3 C J K Liver GE.xlsx (424.17 kB)

DATASET

Figure 3 D 1-wk GK.xlsx (125.98 kB)

DATASET

Figure 3 E Fed Glucose.xlsx (74.95 kB)

DATASET

Figure 3 F Fed Insulin.xlsx (52.61 kB)

DATASET

Figure 3 G DTT FC.xlsx (23.13 kB)

DATASET

Figure 3 H Blood TAG.xlsx (32.92 kB)

DATASET

Figure 3 I 4wk Liver TAG.xlsx (30.97 kB)

DATASET

Figure 3 I 8 wk Liver TAG.xlsx (15.49 kB)

DATASET

Figure 3 L 4-wk Liver GK.xlsx (40.13 kB)

DATASET

Figure 3 L 8-wk Liver GK.xlsx (44.06 kB)

1/0

13 files

DOM FIGURE 3 Chronic effects of AZD1656 on blood glucose, liver triglycerides and glucokinase activity.

dataset

posted on 2020-06-25, 09:38 authored by Brian FordBrian Ford, Loranne AgiusLoranne Agius

A-D: C57BL/6 mice were treated for 1-wk without or with AZD1656 (at 0.3, 1, 3 and 9 mg/kg body wt): A, Blood glucose; B, plasma insulin at the times indicated; C, Liver mRNA levels; D, liver glucokinase activity. Means ± SEM for n=6, * P< 0.05 vs vehicle.
E-L: C57BL/6 mice were treated for 4-wk or 8-wk without (0) or with AZD1656 (1 or 3mg/kg body wt): E, blood glucose; F, plasma insulin; G, Acute (120min) blood glucose lowering by AZD1656 (drug tolerance test); H, blood triglycerides (TAGs); I, liver triglycerides (TAGs); J, liver mRNA after 4-weeks; K, liver mRNA after 8 weeks; L, liver glucokinase activity. Means ± SEM for n= (10-12, E-H) or n=6 (I-L).